Loading market dashboard
MBX Biosciences, Inc. Common Stock
MBXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
CARMEL, Ind. and BURLINGTON, Mass.
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise Company to host Obesity Day on May 11 th featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio $440.0 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass.
Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2026 ended March 31, 2026 ("Q2 2026") prior to the start of trading on May 14, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q2 2026 results with its CEO, CFO, and COO.
CARMEL, Ind. and BURLINGTON, Mass.
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its clients is presenting results of Microbix made quality assessment products ("QAPs™") that help enable full-process quality management of molecular assays to detect human papillomavirus ("HPV") at 2026 PASCV. 2026 PASCV is the annual meeting and principal gathering of the Pan American Society for Clinical Virology, taking place in Clearwater Beach, Florida April 29 to May 1, 2026.
CARMEL, Ind. and BURLINGTON, Mass.
Releasing Episodes of Season Two of "Diagnostics: Beyond the Lab" Podcast MISSISSAUGA, ON / ACCESS Newswire / April 20, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is releasing three episodes of the second season of its podcast titled "Diagnostics: Beyond the Lab." This Microbix podcast series engages with third-party experts to discuss opportunities and challenges facing the diagnostics industry - to inform policy-makers, medical or scientific professionals, and patients.
MISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026. The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and international investors focused on the latest developments in the Canadian healthcare and life sciences sector.
Immune Therapeutics (OTCMKTS:IMUN - Get Free Report) and MBX Biosciences (NASDAQ: MBX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Earnings and Valuation This table compares Immune
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer.
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent corporate progress.
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO).
Drug Substance Manufacturing Methods Modernized MISSISSAUGA, ON / ACCESS Newswire / March 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that the contract development and manufacturing organization ("CDMO") engaged by its funding and commercialization partner, Sequel Pharma, LLC ("Sequel"), has modernized production methods for the active ingredient (i.e., "Drug Substance") of Kinlytic® urokinase ("Kinlytic"), a biologic for dissolving blood clots.
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).
